NVO: 6-K company filing

6-K 1 f6k_052226.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________ FORM 6-K ________________ REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 May 22, 2026 ________________ NOVO NORDISK A/S (Exact name of Registrant as specified in its charter) Novo Allé 1 DK- 2880, Bagsvaerd Denmark (Address of principal executive offices) ________________ Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F Form 20-F ☒ Form 40-F ☐ CHMP recommends EU approval of Wegovy® 7.2 mg in a single-dose pen, providing up to 20.7% mean weight loss 1 · Wegovy® 7.2 mg in a single-dose pen has now been recommended by CHMP for approval in the EU · Novo Nordisk expects to launch Wegovy® 7.2 mg in a single-dose pen in the EU in Q3 2026 · In the STEP UP trial, Wegovy® 7.2 mg demonstrated an average weight loss of 20.7% 1 , and around one-third of patients achieved 25% or greater weight loss · Wegovy® 7.2 mg is already available in the U.S. for adults living with obesity under the brand name Wegovy® HD Bagsværd, Denmark, 22 May 2026 – Novo Nordisk today announced that the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) has adopted a positive opinion, recommending marketing authorisation of Wegovy ® 7.2 mg (once- weekly injectable semaglutide 7.2 mg) in a single-dose pen for people living with obesity. Wegovy ® 7.2 mg is already available in the EU for adults with obesity, dosed as three injections of 2.4 mg, and is based on results from the STEP UP trial programme. In the STEP UP trial, semaglutide 7.2 mg injected o